Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about the regulatory and manufacturing hurdles facing rare disease drug developers.
|Articles|February 2, 2017
- Pharmaceutical Technology-02-02-2017
- Volume 41
- Issue 2
Fluid Imaging System for R&D and Quality Control Applications
The FlowCam 8100 particle imaging and analysis system from Fluid Imaging Technologies features a camera that can capture images at up to 120 frames per second and high-resolution digital images of individual particles and microorganisms measured in real-time based on their actual size and shape.
The FlowCam 8100 particle imaging and analysis system from Fluid Imaging Technologies features a camera that can capture images at up to 120 frames per second and high-resolution digital images of individual particles and microorganisms measured in real-time based on their actual size and shape. The system can sample with volumes as small as 200µL and measure more than 30 different parameters from basic particle size, count, and concentration to color, grayscale, and advanced morphological characteristics such as circularity, elongation, and fiber curl.
The system can be used to detect and analyze protein aggregates and can conduct stability studies and shelf-life simulations, as well as for a variety of other R&D and quality control applications. The FlowCam 8100 includes a computer-controlled syringe pump, quick-connect field of view (FOV) flow cell with holder, and integrated pipette-based sample port with automated rinsing and cleaning. The FlowCam 8100 may also be fitted with the companion ALH automated liquid handling system, which automatically processes up to 96 samples per run without requiring human involvement or supervision.
Articles in this issue
over 9 years ago
A Risk-Based Approach to Stainless Steel Equipment Maintenanceover 9 years ago
Pumping Fluids in Biopharmaceutical Processingover 9 years ago
Moving Forward with Adaptive Licensingover 9 years ago
Collaboration Key to Meeting Excipient GMP Requirementsover 9 years ago
Regulatory Reform Is Not That Simpleover 9 years ago
Mass Spec Sheds New Light on Biologics Drug Developmentover 9 years ago
Evaluating E&L Studies for Single-Use Systemsover 9 years ago
Ensuring Sterility in Small-Scale Productionover 9 years ago
Viewpoint: Challenges and Opportunities for CDMOsRelated to this article
FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic demand for drug manufacturers.
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Ravi Kiran Kaja, PhD, USP, explains what harmonization of extractables and leachables standards looks like in practice.
Jaenisch, Muraru, and Pandey discuss new skills for QC and regulatory teams, plus patient trust, as new approach methodologies reshape pharma.
Nine duloxetine recalls since 2024 show why generic drug manufacturers need route-level nitrosamine risk assessment, not end-product testing alone.
OpenAI acquired Orchestra Bio to pair AI agents that track drug development timelines with its Rosalind life sciences tools, raising oversight questions for pharma teams.
Trending on Pharmaceutical Technology
1
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
2
Nitrosamine Problems and Industry Solutions: PharmTech Explained
3
AAPS PharmSci 360 2026: System Suitability Standards in E&L Testing
4
FDA Approves Bepirovirsen: Why Oligonucleotide CDMOs Should Take Note
5